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Abstract
Background: Recent publications brought up the hypothesis that an infection with Chlamydia
Pneumoniae (CP) might be a major cause of coronary artery disease (CAD). Therefore, we
investigated whether endothelial dysfunction (ED) as a precursor of atherosclerosis might be
detectable in patients with previous infection with CP but without angiographic evidence of CAD.
Methods: We included 16 patients (6 male / 10 female) of 52 consecutive patients with normal
coronary angiography who had typical angina pectoris and pathologic findings in the stress test.
Exclusion criteria were: active smoker, elevated cholesterol, hypertension, age > 65 years, diabetes
mellitus, treatment with ACE-inhibitors, or known CAD. Blood sample analysis for serum titer
against CP (aCP-IgG) was performed after coronary angiography. We looked for endothelial
dysfunction analyzing the diameter of the left anterior descending coronary artery (LAD) before
and after acetylcholine (ACh) i. c. Quantitative analysis of luminal diameter (LD) was performed in
at least two planes during baseline conditions and after ACh for 2 minutes in dosages of 7.2 µg/min
and 36 µg/min with an infusion speed of 2 ml/min. Using Doppler guide wire, the coronary flow
velocity was measured continuously in the LAD. The coronary flow velocity reserve (CFVR) was
measured after 20 µg adenosine i. c.
Results: 10 patients had an elevated aCP-IgG (> 1:8). 6 patients with negative titers (aCP-IgG ≤
1:8) served as control (CTRL). Both groups were comparable in age, gender, angina class, results
of non-invasive stress-test and the baseline values of LD and flow. In the CP positive group 3
patients (30%) did not show an increase of LD after ACh as evidence of ED. In the CTRL group 4
patients (67 %) had ED. There was no association between aCP-IgG and changes of coronary blood
flow after ACh. All patients showed normal CFVR (3.0 ± 0.27) irrespective of their aCP-IgG values.
Conclusion: In patients with typical symptoms of coronary ischemia but without angiographically
visible CAD and absence of other factors affecting the endothelial function, a previous infection
with CP is not associated with endothelial dysfunction.
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Introduction
If coronary angiography is carried out due to pathological
stress-test or angina pectoris, 10% to 20% of the patients
do not reveal any atherosclerotic alteration of the coro-
nary vessel related to the clinical symptoms [1]. As a pos-
sible explanation of this phenomenon, an infectious
mechanism was discussed, which leads to an endothelial
dysfunction (ED) and thus functional impairment of the
coronary circulation [2,3].
The intracellular bacterial pathogen Chlamydia pneumo-
niae (CP) causes respiratory tract infections of increasing
incidence with age [4]. The proof of CP both in atheroscle-
rotic coronary vessels at post-mortem examinations and
also in tissue samples from coronary atherectomy brought
up the hypothesis that an infection with CP is also an
important promoter of atherosclerosis and CAD [5-7]. In
addition, the successful treatment with antibiotics of
patients suffering from unstable angina pectoris sup-
ported this hypothesis [8,9]. CP was accused of damaging
the coronary endothelial cells and therefore causing a
local inflammatory reaction and promoting the sub-
endothelial storage of low density lipoprotein (LDL) cho-
lesterol [10-12].
The ED can be regarded as an early form of CAD before
the detection of angiographically visible alterations
caused by storage of cholesterol in the vessel wall [13].
The lack of dilatation of the coronary vessels during infu-
sion of acetylcholine (ACh) uncovers an ED in vivo. This
method of inducing a paradoxical reaction of the artery
was well evaluated in patients suffering from diabetes
mellitus, hypercholesterolemia, obesity, hypertension, or
CAD, and in smokers [14-17]. Under the medication of
ACE- inhibitors an ED can be attenuated [18].
Therefore, we designed this study including only patients
without any known factor which could influence the
endothelial function except previous CP infection indi-
cated by elevated antibodies. It was our aim to prove
whether there is an association between an infection with
CP and an ED in those patients who did not carry any of
the known risk factors. A positive result would corrobo-
rate the hypothesis of a causal role of CP in atherogenesis.
Methods
Patient selection
All patients had to give written informed consent. The
study was performed with approval of the local ethical
committee of our university. Out of 1144 consecutive
patients who were brought to an elective coronary angiog-
raphy because of typical angina pectoris or a pathological
stress test for the first time, 52 caucasian patients who ful-
filled the following criteria were screened for this study
during a period of 22 months. Exclusion criteria were
myocardial infarction, unstable angina, ECG abnormali-
ties at rest, disorders of wall motion or thickened left ven-
tricular wall in echocardiography, vitiae of the valves, age
≥  65 years, arterial hypertension (systolic blood pressure
at rest ≥  140 mmHg), any type of diabetes mellitus, obes-
ity (body mass index ≥  30), hypercholesterinemia (total
cholesterol ≥  5.0 mmol/l or LDL cholesterol ≥  3.0 mmol/
l), hypetriglyceridemia (triglycerides ≥  5.0 mmol/l), and a
history of smoking during the last 10 years. An acute infec-
tion represented by fever, elevated C-reactive protein
(CRP > 5 mg/dl), or elevated white blood cell count (≥
10,000 / µl) caused exclusion from the study before coro-
nary angiography. We also excluded all patients who were
on medication with ACE inhibitors, anti-hypertensive
drugs, nitrates, hormones, or lipid lowering agents. The
patients gave their written consent for the study 24 hours
before they were transferred to the catheter laboratory.
Study protocol
Coronary angiography was performed in standard fashion
via femoral approach with a 5F diagnostic catheter. We
saw atherosclerotic lesions of at least one coronary artery
in 34 patients (65.4%). They were excluded and an angi-
oplasty was carried out where necessary. The following
measurements were performed in the remaining 18
patients (34.6%) in whom we did not find any alterations
of the coronary arteries (exclusion of atherosclerotic
plaque in all projections).
After intra coronary administration of 10.000 IE heparin,
we placed a 0.014 inches Doppler guide-wire (Flowire™,
Cardiometrics, USA) in the mid LAD. The tip of the wire
was positioned in a straight vessel segment at least 1 cm
from a departure of any relevant side branch. In 2 patients
we stopped the testing due to complications: one patient
showed a coronary spasm after insertion of the Doppler
wire, another patient developed a bradycardia of 35 beats
/ min and a pressure drop immediately after starting the
ACh infusion. After removal of the wire and termination
of the ACh infusion, these complications were completely
reversible within a few seconds. However, these two
patients were excluded from further examinations and
from the study. In the remaining 16 patients (30.8 %) the
measurements according to the study protocol were car-
ried out without any complications.
The luminal diameter (LD) was measured 5 mm distal to
the tip of the Doppler wire in two orthogonal planes by
means of automatic quantitative coronary angiography
(QCA). Automatic contour detection was performed with
a geometric edge differentiation technique [19]. For pre-
vention of a study bias, the automated QCA was per-
formed by an independent cardiologist without
knowledge of the antibody titer against ChlamydiaCardiovascular Ultrasound 2005, 3:12 http://www.cardiovascularultrasound.com/content/3/1/12
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pneumoniae. Each coronary angiography was performed
in the same projection as the baseline procedure.
After recording a stable Doppler baseline signal, we
infused acetylcholine (ACh) (Miochol™; CIBA Vision,
Switzerland) at a dose of 7.2 µg/min through the catheter
into the LAD for two minutes. Assuming a blood flow in
the LAD of 80 ml/min, we estimated a final ACh concen-
tration in the coronary bed of 1/2 × 10-6 mol/l (= dose 1,
ACh D1). Careful attention was paid to the calculation of
catheter dead space to ensure accurate delivery of acetyl-
choline to the coronary ostium. Subsequently, coronary
angiography was carried out in the same projection as at
the baseline. The ACh infusion was stopped for at least 3
minutes before proceeding. After reaching stable baseline
conditions, i. c. infusion of 2 ml/min of ACh in a concen-
tration of 36 µg/min aiming at a concentration of 1/4 ×
10-5 mol/l (= dose 2, ACh D2) was started for another 2
minutes. Angiography was repeated immediately after
each infusion.
After another recovery period of 3 minutes, we gave a con-
tinuous infusion of saline (NaCl 0.9 %) with an infusion
rate of 2 ml/min. After restoring the baseline following the
angiography, we injected 0.2 mg of nitrotriglycerin (NTG)
i. c. and performed a final coronary angiography in the
same projections as before.
The average coronary peak flow velocity (APV) was regis-
tered continuously by means of a Doppler wire during the
complete examination. Attention was paid to insure that
APV had returned to baseline values between each meas-
urement. At the end of the examination we injected 20 µg
adenosine i.c. recording the maximum rise of APV in com-
parison to the baseline value which yields the coronary
flow velocity reserve (CFVR). The CFVR measurement was
carried out at least twice, and the mean value was calcu-
lated for further analysis.
Calculation of coronary blood flow (CBF)
Coronary blood flow (CBF) was calculated out of the aver-
age peak flow velocity (APV) measured by Doppler guide-
wire in the mid LAD. By offline analysis with QCA we cal-
culated the average LD distal to the tip of the Doppler
wire. Multiplying the square of 0.5 × LD with π  we
obtained the luminal area (LA) of the vessel at the site of
measurement. LA × APV × 0.5 results in the CBF. This
method of calculation of CBF has been evaluated in vitro
and in vivo [20,21].
Serological analysis of antigenic titers against Chlamydia 
pneumoniae
Following the catheter examination we took 10 ml of
blood for the antibody determination against CP. Testing
for anti-CP antibody (IgG) we used a standard micro-
immuno-fluorescence (MIF) test on consecutive dilution
rows. We used the MIF serology with the antigens
Chlamydia pneumoniae (TW183) antigen and Chlamy-
dia trachomatis (type D) in order to exclude cross reacting
antibodies. The serum tests were performed in a double-
blinded setting. The researcher who performed the sero-
logical analysis did not receive any knowledge of the
results of the coronary angiography and the flow measure-
ments and vice versa. The patients were retrospectively
allotted in two groups according to their aCP-IgG values:
Those patients with an aCP-IgG ≤  1:8 formed the group of
CP negative patients, individuals with aCP-IgG > 1:8 were
included in the CP positive group since they were sup-
posed to suffer from a previous infection with CP. The
results of the Chlamydia trachomatis MIF test were con-
sidered in this grouping.
Statistical analysis
All values are expressed as mean ± standard deviation
(SD). P values were calculated using a two-tailed student's
t test for statistical analysis of continuous variables by
Excel™ (Mircosoft Co., USA). Multivariate logistic regres-
sion analysis including aCP-IgG, sex and age as risk factors
of ED and two-tailed exact Fisher's test were performed
using SPSS™ (SPSS Inc., USA). A p value ≤  0.05 was con-
sidered statistically significant.
Results
The analysis of the serum probes showed increased aCP-
IgG values (>1:8) in 10 patients (62.5%). They formed the
subgroup of the CP positive individuals. The remaining 6
patients (37.5%) had negative aCP-IgG titers (≤  1:8) and
served as the control group. All 16 patients in the study
were negative (≤  1:8) against Chlamydia trachomatis
(type D) in the MIF test.
The baseline data of all patients are summarized in table
1. The results of the testing in the catheter laboratory are
listed in table 3. Coronary blood flow velocity was 18.9 ±
4.49 cm/sec in our study population. The APV increased
to 35.0 ± 12.08 cm/sec during middle dosage and 42.1 ±
11.49 cm/sec during the infusion of the high dosage of
ACh. After the bolus injection of 0.2 mg NTG, we meas-
ured an APV of 27.7 ± 8.22 cm/sec. There was no signifi-
cant difference in the APV values between the 2 groups.
Among the negative control group without previous con-
tact with CP, four patients (66.7%) did not show any
increase of luminal diameter (LD) during ACh infusion,
what was judged as an ED (Figure 1). Three patients
(30%) of the CP positive subgroup did not show an
increase of the LD (Figure 2). The two-tailed exact Fisher's
test did not unveil any significant difference between the
two groups (p = 0.302) as shown in table 2. For the final
measurement of the CFVR, we recorded a 2.5 to 3.5 foldCardiovascular Ultrasound 2005, 3:12 http://www.cardiovascularultrasound.com/content/3/1/12
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increase of the APV (3.0 ± 0.27) after i.c. injection of 20 µg
adenosine. There was no association between the occur-
rence of an ED and the height of the CFVR (p = 0.258) or
between the aCP-IgG and the CFVR values (p = 0.735). We
did not find any correlation between CFVR and the flow
velocity increase during high dose ACh infusion (r = -
0.19).
Discussion
In this prospective study we investigated whether a previ-
ous infection with Chlamydia pneumonia is associated
with an endothelial dysfunction of the coronary vessels
before the presence of atherosclerosis. It was our intention
to exclude all patients with known risk factors for athero-
sclerosis and endothelial dysfunction (e.g. hypertension,
hyperlipidemia, smoking, and diabetes). In addition,
those patients who took medication which could have
influenced the endothelial function were excluded. Six-
teen patients without any angiographically visible athero-
sclerotic alteration but typical signs of coronary ischemia
at stress were included in the study. We evaluated the
capability of the coronary endothelium to promote a
vessel dilatation in this highly selected group of patients.
A lack of flow mediated diameter increase of ≥  5% was
Table 1: Baseline characteristics of study patients, and number of patients with pathologic findings in bicycle or scintigraphy stress-
test.
All patients CP positive CP negative
Number 16 10 (62.5 %) 6 (37.5 %)
Age (years) 50.7 ± 7.02 53.2 ± 6.48 47.0 ± 6.08
Sex (male) 6 male (37.5 %) 4 male (40 %) 2 male (33.3 %)
Angina class (CCS) 2.4 ± 0.48 2.4 ± 0.49 2.3 ± 0.47
Pathologic ECG in bicycle 
stress-test
12 (75 %) 7 (70 %) 5 (83.3 %)
Pathologic scintigraphy 5 (31.3 %) 3 (30 %) 2 (33.3 %)
Total Cholesterol levels 4.0 ± 0.58 mmol/l
154.1 ± 22.41 mg%
4.1 ± 0.68 mmol/l
157.5 ± 26.48 mg%
3.8 ± 0.28 mmol/l
148.4 ± 10.87 mg%
Systolic blood pressure 121 ± 12.0 mmHg 120 ± 11.7 mmHg 122 ± 12.4 mmHg
Smoking history (last 10 
years)
All negative All negative All negative
Total Cholesterol levels were below 200 mg% (5.2 mmol/l) in all patients, the systolic blood pressure did not exceed 139 mmHg in any case.
CP: Chlamydia pneumoniae {values are mean ± SD, % of each group}.
Table 3: Coronary blood flow and vessel diameter.
All patients CP positive p CP negative
CBF (ml / min) (+/- percentchange)
baseline 22.6 ± 14.39 22.0 ± 13.80 →  0.503 ← 23.4 ± 15.28
ACh D1 39.6 ± 21.21 (+75.2%) 40.4 ± 22.34 (+83.6%) →  0.172 ← 38.5 ± 19.33 (+64.5%)
ACh D2 48.7 ± 30.34 (+115.5%) 51.6 ± 27.82 (+134.5%) →  0.177 ← 41.3 ± 34.78 (+76.5%)
NaCl (control) 23.1 ± 12.15 (+2.2%) 22.1 ± 12.38 (+0.4%) →  0.697 ← 24.7 ± 11.57 (+5.5%)
NTG 40.3 ± 23.06 (+78.3%) 39.5 ± 20.74 (+79.5%) →  0.696 ← 41.0 ± 24.74 (+75.2%)
Vessel diameter (mm)
(+/- percent change)
baseline 2.53 ± 0.50 2.55 ± 0.50 →  0.773 ← 2.51 ± 0.48
ACh D1 2.55 ± 0.50 (+0.8%) 2.56 ± 0.52 (+0.4%) →  0.658 ← 2.54 ± 0.46 (+1.2%)
ACh D2 2.54 ± 0.61 (+0.3%) 2.60 ± 0.62 (+2.0%) →  0.289 ← 2.46 ± 0.58 (-2.0%)
NaCl (control) 2.54 ± 0.45 (+0.1%) 2.52 ± 0.48 (-1.1%) →  0.543 ← 2.58 ± 0.39 (+2.7%)
NTG 2.88 ± 0.52 (+13.8%) 2.88 ± 0.47 (+13.0%) →  0.801 ← 2.89 ± 0.60 (+15.1%)
CFVR 3.0 ± 0.27 3.1 ± 0.31 →  0.652 ← 3.0 ± 0.10
Coronary blood flow (CBF) and vessel diameter before (baseline) and after i. c. infusion of acetylcholine (ACh) at medium dose (ACh D1: 7.2 µg/
min →  1/2 × 10-6 mol/l) and high dose (ACh D2: 36 µg/min →  1/4 × 10-5 mol/l), 0.2 mg nitroglycerin (NTG), continuous infusion of saline (NaCl 0.9 
% at 2 ml/min) served as control. The comparison of the CBF, and of the vessel diameter with the corresponding baseline value is expressed as 
percent change. CFVR: coronary flow velocity reserve (adenosine i. c. versus baseline), CP: Chlamydia pneumoniae. {values are mean ± SD, p values 
of two-tailed student's t-test}Cardiovascular Ultrasound 2005, 3:12 http://www.cardiovascularultrasound.com/content/3/1/12
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interpreted as an ED. Since we did not find a higher inci-
dence of ED in those patients who had a previous CP
infection than in the patients in the CP negative control
group, we disproved our hypothesis that CP induces an
endothelial damage or even disturbs the endothelial func-
tion before visible atherosclerotic changes take place.
We observed a relatively large proportion of so-called
"exclusion of CAD" among the 52 patients who were
screened according to the strict inclusion criteria. Previous
angiography studies reported a prevalence of negative cor-
onary angiograms of 10% to 20% in comparable popula-
tions [1]. In contrast to predominantly male patient
populations in catheter laboratories, we viewed two thirds
of female individuals in our study collective. Women
show negative coronary angiograms more often than men
[22,23]. Furthermore, our patients were relatively young
which may also explain this relatively large proportion of
negative coronary angiograms. On the other hand, all
patients suffered from typical symptoms of coronary
ischemia such as angina pectoris, ECG changes, or patho-
logic findings in non-invasive stress test. Another limita-
tion of our study is the relatively low sample size due to
difficulties in recruiting patients. We screened 1144
patients for the study, but only 18 patients fulfilled the
strict inclusion criteria.
The CP positive group and the CP negative group were
comparable in terms of age, gender, angina class, and
non-invasive stress-test results. The tendency of a higher
proportion of women to be CP positive was statistically
insignificant (p: 0.172). However, there was no significant
difference between the two groups regarding vessel diam-
eter and flow velocity at the baseline and after administra-
tion of nitroglycerin. The average baseline APV of 18.9 ±
4.49 cm/s with an increase to 27.7 ± 8.22 cm/s is consist-
ent with values reported in the literature [24]. During ACh
infusion, we even recorded a higher increase of LD in
patients with elevated aCP-IgG compared to the CP nega-
tive individuals, but there was no significant difference
here either (Figure 3). We observed a lack of vasodilata-
tion during ACh in 67 % of the CP negative and 30 % of
the CP positive patients (p 0.302). Therefore, we were not
able to verify the hypothesis that a previous infection with
CP leads to a higher incidence of endothelial dysfunction
among patients with normal coronary arteries.
The increase of APV to 300 % after adenosine was
recorded among all patients irrespective of the presence of
ED or the CP titer status. An average CFVR of 3.0 ± 0.27
indicates normal coronary blood flow regulation of the
arteriolar coronary vessels of the study patients [24]. We
conclude that a previous infection with CP does not influ-
ence the dilatory capacity of the arteriolar bed of the cor-
onary circulation represented by the CFVR.
Non of our patients showed any signs of atherosclerotic
lesions of a coronary vessel in the angiogram. Intra-vascu-
lar ultrasound would have been more sensitive to uncover
changes of the integrity of the vessel wall in some patients
Decreased vessel diameter (62% of baseline value) during acetylcholine (36 µg/min) i. c Figure 1
Decreased vessel diameter (62% of baseline value) during acetylcholine (36 µg/min) i. c. Continuous recording of flow velocity 
in this Chlamydia pneumoniae positive patient after i. c. ACh infusion (ACh D1: 7.2 µg/min, ACh D2: 36 µg/min).
2
Ach D1 Ach D2Cardiovascular Ultrasound 2005, 3:12 http://www.cardiovascularultrasound.com/content/3/1/12
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despite a negative coronary angiogram [25]. However, the
endothelial function tested with ACh is one of the most
sensitive methods for detecting early damage of the endo-
vascular structure on the basis of physiologic function
[26].
In patients suffering from CAD, the presence of ED pre-
dicts an enlarged cardiovascular event rate [27]. Since
atherosclerosis is considered to be a chronic inflamma-
tion of the artery vessel wall, it should be the interaction
of CP with cells of the vasculature that can result in a local
inflammatory response. It was reported that CP positive
patients are in danger of having a higher cardiovascular
event rate [8]. Furthermore, supporting the hypothesis of
amplification of the progression of atherosclerosis by mis-
balance in the immune response, a correlation between
high levels of aCP-IgG and acute coronary syndrome was
demonstrated recently in a study on 830 patients [28].
Chlamydia pneumoniae infected patients with coronary
artery sclerosis showed higher re-stenosis rates after a bal-
loon angioplasty, but not after a coronary stent implanta-
tion [29]. However, we did not uncover an increased
number of patients with ED among the individuals with
CP antibodies. Therefore, we postulate that CP is not
envolved in the early atherosclerotic cascade. The persist-
ent CP infection of immune cells (T-cells, monocytes and
macrophages) and non-immune cells (endothelial cells
and smooth muscle cells) may contribute to a cascade of
inflammatory mediators leading to an enhanced tissue
remodeling of the arterial intima and instability of athero-
Vessel diameter of all 16 patients at baseline, during i. c Figure 2
Vessel diameter of all 16 patients at baseline, during i. c. infusion of acetylcholine (ACh) with 7.2 µg/min (ACh D1), and with 36 
µg/min (ACh D2), during NaCl (0.9% 2 ml/min i. c.), and after 0.2 mg nitrotriglycerin (NTG) i. c. Patients without an elevated 
IgG serum titer against Chlamydia pneumoniae (CP negative) are presented by dotted lines.
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sclerotic plaques [30-33]. We would therefore conclude
that a chronic infection with CP is not a major cause of
coronary artery disease. The patho-physiologic link
between CP infection and arteriosclerosis I still under dis-
cussion [34]. Recently published trials including more
than 8,000 patients did not show any evidence for the
Relative changes in coronary blood flow (+ / - standard error of mean) The dotted line presents patients with previous infec- tion with Chlamydia pneumoniae (CP) Figure 3
Relative changes in coronary blood flow (+ / - standard error of mean) The dotted line presents patients with previous infec-
tion with Chlamydia pneumoniae (CP). The bold line shows the results in the CP negative patients. The curves represent the 
relative changes compared to baseline during i. c. infusion of acetylcholine (ACh) with 7.2 µg/min (ACh D1), with 36 µg/min 
(ACh D2), and during NaCl (0.9% 2 ml/min i. c.)
Table 2: Changes of vessel diameter after i. c. infusion of acetylcholine (ACh D2: 36 µg/min) compared with baseline diameter.
n = 16 CP IgG < 1:16 (CP negative) CP IgG ≥  1:16 (CP positive)
Increase of vessel diameter 2 (33 %) 7 (70 %)
No increase of vessel diameter 4 (67 %) 3 (30 %)
The two groups were allotted according to their Chlamydia pneumoniae (CP) IgG serum titer. Two-tailed exact Fisher's test did not show any 
significant difference between both groups (p = 0.302).
0%
50%
100%
150%
200%
250%
300%
baseline ACh D1 ACh D2 NaCl
Relative changes in coronary blood flowCardiovascular Ultrasound 2005, 3:12 http://www.cardiovascularultrasound.com/content/3/1/12
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hypothesis that coronary artery disease is caused by an
infection with CP and antibiotic therapy is indicated
[35,36]. The present model includes the involvement of
CP in the secondary phase of atherogenesis including
inflammation, fibrous plaque formation, plaque rupture,
and thrombosis. Recent meta-analysis questioned any rel-
evance of a CP infection in the early course of CAD [37].
Conclusion
To our understanding of the mechanism of CP involve-
ment in atherogenesis, we interpret the results of our
study in combination with the present knowledge about
CP as favoring a possible contributory rather than a causal
role. However, there is need for further studies to
enlighten the early pathomechanisms of chlamydial
infection of the endothelium, including signaling path-
ways in the genesis and the progression of coronary artery
disease.
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